Slide 1: HY17 Interim Results Presentation
HY17 Interim Results Presenta3on For the six months to 30 September 2016 24 November 2016 David Darling, CEO
Slide 2: Commercial Pathway
COMMERCIAL PATHWAY Primary focus for 1H17: Con3nuing to establish User Programmes, transi3on exis3ng User Programmes to commercial customers Pacific Edge 2017 Interim Results Presenta3on 2
Slide 3: 2016 Milestones
2016 MILESTONES Excellent Progress in 1H17 Awarded Federal Supply Schedule, PosiGve and compelling results in negoGated contract price for access Kaiser Permanente study to Veterans AdministraGon New commercial partnership with Approved provider to Tolmar Australia TRICARE JAN FEB MAR APRIL MAY JUNE
Slide 4: F17 First Half Highlights
F17 FIRST HALF HIGHLIGHTS Excellent Progress with Expanded Product Offer Extended private insurance cover TransformaEonal Customers and public healthcare uptake in New Zealand Cxbladder Detect and Triage Veterans AdministraGon and now available in all targeted TRICARE commercial underway; markets. Ne
Slide 5: Markets
MARKETS USA HEALTHCARE MARKET PROGRESS AND NEXT STEPS USA: The world’s largest 18 sales execu3ves focused on 19 targeted sales regions healthcare market COMPLETED √ Over 10,000 urologists and millions of VA: Entered into contract, set contract price, sales team COMPLETED √ poten3al clinical opportun
Slide 6: Veterans Administration (VA)
VETERANS ADMINISTRATION (VA) ONE OF PACIFIC EDGE’S KEY CUSTOMERS PROGRESS AND NEXT STEPS VETERANS ADMINISTRATION Signed Federal Supply Schedule Agreement on (Feb 2016) COMPLETED √ Nego3ated contract price for tests (2016) COMPLETED √ • Federal funded healthcare for veterans and their families Iden3fi
Slide 7: TRICARE
TRICARE ONE OF PACIFIC EDGE’S KEY CUSTOMERS PROGRESS AND NEXT STEPS TRICARE Approved as a provider (October 2016) COMPLETED √ Nego3ated contract price for tests (October 2016) COMPLETED √ • Healthcare programme for USA uniformed service members and their In Progress The Pacific Edge USA sales team ar
Slide 8: Kaiser Permanente
KAISER PERMANENTE POTENTIALLY TRANSFORMATIONAL FOR THE COMPANY PROGRESS AND NEXT STEPS KAISER PERMANENTE Signed large scale User Programme COMPLETED √ Recruitment of pa3ents completed on 3me in 2016 COMPLETED √ • An integrated managed care provider, headquartered in California Cleaning, valida3on an
Slide 9: Centers for Medicare and Medicaid/Other Customers
CENTERS FOR MEDICARE AND MEDICAID/OTHER CUSTOMERS FY17 OBJECTIVES AND PROGRESS CMS Con3nue to progress discussions with Centers for Medicare and CENTERS FOR MEDICARE AND MEDICAID Medicaid Services (CMS) • Con3nuing to follow regulatory process to gain access to CMS • USA federal agency which adminis
Slide 10: Other Markets
OTHER MARKETS NEW ZEALAND, AUSTRALIA, SOUTH EAST ASIA FY17 OBJECTIVES AND PROGRESS AUSTRALIA Work with Tolmar Australia to build awareness and increase sales of Cxbladder tests in Australia • Tolmar Australia’s nine dedicated urology sales execu3ves leveraging their exis3ng networks; targe3ng large
Slide 11: Products
PRODUCTS Our Products Now Span The En3re Clinical Pathway - A World First FY17 OBJECTIVES AND PROGRESS CXBLADDER TRIAGE NZ Launch Dec 14 Rollout of Cxbladder Monitor into the United States and USA Rollout 2015/16 Australia • Australia rollout completed • USA rollout – soo launch underway to targeted
Slide 12: Product Development and Launch Timeline
PRODUCT DEVELOPMENT AND LAUNCH TIMELINE Full USA commercial launch Final checks on commercial model NZ Launch USA SoW Launch Validate laboratory processes Small group of targeted urologists Build CLIA regulatory package Develop markeGng collateral Finalise USA commercial package Sign off on laborator
Slide 13: Cxbladder NZ/USA Launch Timings
CXBLADDER NZ/USA LAUNCH TIMINGS 2016 has been the busiest year yet for product launches and rollout 2012 2013 2014 2015 2016 2017 2018 Cxbladder DETECT NZ Launch USA Launch Cxbladder TRIAGE NZ Launch Soo USA Launch Full USA Launch Cxbladder MONITOR NZ Launch Soo Full USA Launch Cxbladder RESOLVE NZ
Slide 14: Sales Channels
SALES CHANNELS BUILD AWARENESS, ENCOURAGE ADOPTION, TRANSITION TO COMMERCIAL CUSTOMER FY17 OBJECTIVES AND PROGRESS Bladdercancer.me In Progress ConEnue to iniEate new User Programmes and transiEon Online pa3ent community sponsored by early adopters into commercial customers Pacific Edge Enables Pacifi
Slide 15: First Half FY17 Revenue
FIRST HALF FY17 REVENUE 5 REVENUE Results consistent with previous growth and annual 4.5 4 trends, with a sooer first half year and a stronger 3.5 67% increase in second half year 3 operaGng 2.5 revenue NZ$Million 2 TOTAL REVENUE $3.8M: Strong year on year growth, 1.5 compared to pcp 1 up 42% on pcp
Slide 16: 1H16: 1H17 Revenue Bridge
1H16: 1H17 REVENUE BRIDGE REVENUE GROWTH • Posi3ve growth in product sales, predominantly FX, Interest, Grant in the USA: Other funding • No contribu3on yet from new customers – VA and TRICARE OperaGng Revenue • USA product growth from one product only Growth being fully available in market during t
Slide 17: Revenue Outlook and Drivers for Second Half FY17
REVENUE OUTLOOK AND DRIVERS FOR SECOND HALF FY17 Revenue Uplio Expected In Line With Annual Trends Growth will be driven by: USA: • Less seasonal impact in second half compared to first half which includes summer holidays • Uplio as number of people with private healthcare insurance reach their deduc
Slide 18: First Half FY17 Investment into Growth
FIRST HALF FY17 INVESTMENT INTO GROWTH HY17 HY16 Change OPERATING EXPENSES TOTAL REVENUE 3,813 2,692 42% Con3nued investment into four strategic areas: Laboratory Expenses 654 394 66% • People – expanded sales team from 12 to 18 sales execu3ves compared to pcp) Research 2,470 1,932 28% • Products –
Slide 19: Funding for Growth
FUNDING FOR GROWTH NET OPERATING CASHFLOWS HY17 HY16 NET OPERATING CASHFLOW Receipts from customers and grant 2,727 821 Net opera3ng cashflow at a similar level to the previous providers two six month periods Interest received 316 194 232% increase in receipts from revenue and grant income Payments t
Slide 20: Looking Forward
LOOKING FORWARD PRIORITIES FOR 2H16 MARKETS CUSTOMERS • Primary focus on USA • Complete joint analysis of Kaiser Permanente User • NZ: Con3nue to encourage uptake by DHBs Programme study, submit for publica3on, bring on board as • Australia: Conversion of User Programmes with early commercial custom
Slide 21: Cxbladder Now Dominates the Clinical Pathway
CXBLADDER NOW DOMINATES THE CLINICAL PATHWAY Pacific Edge is the only company in the world to offer a suite of proprietary molecular diagnosEc tests for bladder cancer, from assessment and detecEon to management and monitoring for recurrence of the disease • Pacific Edge is the only company to have thr
Slide 22: Question and Answer
QUESTION AND ANSWER Pacific Edge 2017 Interim Results Presenta3on 22
Slide 23: Contact details
www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com David Darling Chief ExecuGve Officer Pacific Edge Limited Tel: +64 3 479 5802 Mobile: +64 21 797981 Email: dave.darling@pelnz.com Pacific Edge 2017 Interim Results Presenta3on
Slide 24: Disclaimer
DISCLAIMER InformaEon The informaGon in this presentaGon is an overview and does not contain all informaGon necessary to make an investment decision. It is intended to consGtute a summary of certain informaGon relaGng to the performance of Pacific Edge Limited . The informaGon in this presentaGon is